Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Edesa Biotech, Inc. - Common Shares (NQ:EDSA)

1.732 -0.008 (-0.46%)
Streaming Delayed Price Updated: 10:12 AM EST, Nov 4, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Edesa Biotech, Inc. - Common Shares

< Previous 1 2 3 4 5 Next >
Edesa Biotech to Present at the H.C. Wainwright Global Investment Conference
TORONTO, ON / ACCESSWIRE / September 9, 2021 / Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmaceutical company focused on inflammatory and immune-related diseases, announced today that... 
From Edesa Biotech
Via AccessWire
Topics Intellectual Property
Edesa Biotech Provides Update For COVID-19 Antibody Trial
Edesa Biotech Inc (NASDAQ: EDSA) issued an update for the Phase 2/3 study evaluating its monoclonal antibody candidate, EB05, as single-dose therapy for... 
Via Benzinga
Edesa Biotech Enrolls More Than 525 COVID-19 Patients Ahead of Schedule
- Delta variant contributes to rapid enrollment amid growing scientific rationale for targeting Toll-like Receptor 4 (TLR4) Blinded interim analysis from Phase 2/3 study expected in current quarter... 
From Edesa Biotech
Via AccessWire
Topics Intellectual Property
Edesa Biotech Reports Fiscal 3rd Quarter 2021 Financial Results
TORONTO, ON / ACCESSWIRE / August 13, 2021 / Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmaceutical company focused on inflammatory and immune-related diseases, today reported financial... 
From Edesa Biotech
Via AccessWire
Topics Intellectual Property
Edesa Biotech Extends Dermatitis Study to Canada
TORONTO, ON / ACCESSWIRE / July 13, 2021 / Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmaceutical company focused on inflammatory and immune-related diseases, today announced that the... 
From Edesa Biotech
Via AccessWire
Topics Intellectual Property
Edesa Biotech Team Expands Leadership Team with Key Manufacturing Appointment
TORONTO, ON / ACCESSWIRE / June 23, 2021 / Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmaceutical company focused on inflammatory and immune-related diseases, today announced the... 
From Edesa Biotech
Via AccessWire
Topics Intellectual Property
Edesa Biotech Reports Favorable Review of COVID-19 Study
TORONTO, ON / ACCESSWIRE / June 18, 2021 / Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmaceutical company focused on inflammatory and immune-related diseases, today reported that an... 
From Edesa Biotech
Via AccessWire
Topics Intellectual Property
Edesa Biotech to Attend BIO Digital 2021
TORONTO, ON / ACCESSWIRE / June 8, 2021 / Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmaceutical company focused on inflammatory and immune-related diseases, announced today that the... 
From Edesa Biotech
Via AccessWire
Topics Intellectual Property
Edesa Biotech's EB01 Shows Encouraging Interim Results In Dermatitis Trial
Edesa Biotech Inc's (NASDAQ: EDSA) EB01 has met a key interim study parameter as part of an adaptive Phase 2b trial evaluating EB01 as monotherapy... 
Via Benzinga
Edesa Biotech Reports Positive Interim Results in Dermatitis Trial
TORONTO, ON / ACCESSWIRE / June 3, 2021 / Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmaceutical company focused on inflammatory and immune-related diseases, today announced that the... 
From Edesa Biotech
Via AccessWire
Topics Intellectual Property
Edesa Biotech to Join Panel Discussion at Industry Event
TORONTO, ON / ACCESSWIRE / May 28, 2021 / Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmaceutical company, announced today that Dr. Par Nijhawan, Chief Executive Officer, is scheduled to... 
From Edesa Biotech
Via AccessWire
Topics Intellectual Property
Edesa Biotech Reports Fiscal 2nd Quarter 2021 Results
TORONTO, ON / ACCESSWIRE / May 14, 2021 / Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmaceutical company focused on inflammatory and immune-related diseases, today reported financial... 
From Edesa Biotech
Via AccessWire
Topics Intellectual Property
12 Health Care Stocks Moving In Tuesday's Intraday Session
Gainers Cocrystal Pharma (NASDAQ:COCP) stock rose 143.41% to $3.02 during Tuesday's regular session. Trading volume for Cocrystal Pharma's stock is 378.0 million... 
Via Benzinga
Edesa Biotech to Host Key Opinion Leader Webinar on EB05 for the Treatment of Acute Respiratory Distress Syndrome
Virtual event scheduled for Thursday, April 29 at 1 pm Eastern Time TORONTO, ON / ACCESSWIRE / April 22, 2021 / Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmaceutical company focused on... 
From Edesa Biotech
Via AccessWire
Topics Intellectual Property
< Previous 1 2 3 4 5 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.